

Functional Metabolic Map of *Faecalibacterium prausnitzii*, a Beneficial Human Gut Microbe

Almut Heinken,^{a,b} M. Tanweer Khan,^c Giuseppe Paglia,^d Dmitry A. Rodionov,^{d,e} Hermie J. M. Harmsen,^c Ines Thiele^{a,b}

Luxembourg Center for Systems Biomedicine, University of Luxembourg, Belval, Luxembourg^a; Center for Systems Biology, University of Iceland, Reykjavik, Iceland^b; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands^c; Sanford-Burnham Medical Research Institute, La Jolla, California, USA^d; A. A. Kharkevich Institute for Information Transmission Problems, Russian Academy of Sciences, Moscow, Russia^e

The human gut microbiota plays a central role in human well-being and disease. In this study, we present an integrated, iterative approach of computational modeling, *in vitro* experiments, metabolomics, and genomic analysis to accelerate the identification of metabolic capabilities for poorly characterized (anaerobic) microorganisms. We demonstrate this approach for the beneficial human gut microbe *Faecalibacterium prausnitzii* strain A2-165. We generated an automated draft reconstruction, which we curated against the limited biochemical data. This reconstruction modeling was used to develop *in silico* and *in vitro* a chemically defined medium (CDM), which was validated experimentally. Subsequent metabolomic analysis of the spent medium for growth on CDM was performed. We refined our metabolic reconstruction according to *in vitro* observed metabolite consumption and secretion and propose improvements to the current genome annotation of *F. prausnitzii* A2-165. We then used the reconstruction to systematically characterize its metabolic properties. Novel carbon source utilization capabilities and inabilities were predicted based on metabolic modeling and validated experimentally. This study resulted in a functional metabolic map of *F. prausnitzii*, which is available for further applications. The presented workflow can be readily extended to other poorly characterized and uncharacterized organisms to yield novel biochemical insights about the target organism.

The human gut microbiome is dominated by four phyla, the *Bacteroidetes* and *Firmicutes*, which make up 90 to 99% of the identified phylotypes in metagenomic analysis, as well as the *Actinobacteria* and the *Proteobacteria* (1), yet it contains an estimated 1,000 species (2). The Human Microbiome Project (3) catalog currently contains over 700 reference genomes of human gut microbes, most of which are still biochemically uncharacterized.

Among firmicutes, *F. prausnitzii* is one of the most abundant species in humans, accounting for around 8% of the total colonic microbiota (4), and plays an important role in the healthy gut. Indeed, *F. prausnitzii* was found to be underrepresented in the gut microbiotas of patients with Crohn's disease, active ulcerative colitis, alternating-type irritable bowel syndrome (IBS-A) (5), and diabetes type II (6, 7). One of its main fermentation products, the short-chain fatty acid butyrate, serves as the main energy source for colonocytes and has anti-inflammatory properties (8). *F. prausnitzii* has been proposed as a potential probiotic for treatment of gut inflammation, as the microbe stimulates the expression of the anti-inflammatory cytokine interleukin 10 (IL-10) in peripheral blood mononuclear cells *in vitro*. Furthermore, cell supernatants of *F. prausnitzii* culture reduced the secretion of pro-inflammatory IL-8 and strongly inhibited NF- κ B activation in cancer cells (9). Butyrate alone did not provoke the observed inhibitory effect (9), demonstrating that *F. prausnitzii* likely secretes an unknown anti-inflammatory metabolite apart from butyrate.

The fermentation pathways and butyrate-producing mechanisms of *F. prausnitzii* are well described (10). Under *in vitro* conditions, *F. prausnitzii* growth is strongly stimulated in the presence of acetate (11). However, other metabolic pathways have been comparatively poorly studied, and its growth requirements are not known (12). *F. prausnitzii* is known to utilize a variety of carbohydrates, including the prebiotic inulin, apple pectin, and some host-derived carbon sources, such as D-glucosamine and N-acetyl-D-glucosamine (11, 13, 14).

Genome-scale metabolic reconstructions (GENREs) are frequently used in systems biology. These GENREs are generated in a bottom-up manner and capture the genetic, genomic, and biochemical traits of a given organism. The number of well-curated GENREs is increasing steadily (15). Particularly well represented are microbes colonizing the human body (16). GENREs have been applied successfully to the elucidation of biochemical and metabolic properties of a variety of microorganisms, including the Fe(III) reducer *Geobacter sulfurreducens* (17), the photosynthetic alga *Chlamydomonas reinhardtii* (18), and the human pathogen *Mycoplasma pneumoniae* (19).

Another application of GENREs is the investigation of microbial growth requirements and design of minimal media. For instance, constraint-based modeling was used for minimal medium design for the lactic acid bacterium *Lactococcus lactis* (20), for the eukaryotic pathogen *Leishmania major*, for which improvements to gene annotations were also proposed (21), and for the pathogenic bacterium *Neisseria meningitidis* (22). However, the described approaches targeted moderately well studied to well-studied organisms. For *N. meningitidis*, the amount of literature on growth requirements is particularly high, which facilitated design of a minimal medium (22). Developing minimal media for poorly studied organisms remains challenging, as the predictive potential

Received 17 April 2014 Accepted 28 June 2014

Published ahead of print 7 July 2014

Address correspondence to Ines Thiele, ines.thiele@uni.lu.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/JB.01780-14>.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JB.01780-14

of a metabolic reconstruction depends on manual curation of the draft reconstruction derived from genome annotation (23).

The aim of the present study was to combine state-of-the-art computational and experimental techniques to elucidate metabolic capabilities of *F. prausnitzii* type strain A2-165. We assembled a highly curated and validated metabolic reconstruction from the genome sequence, limited biochemical literature, *in vitro* culture, and metabolomic measurements. The reconstruction was used to develop a chemically defined medium (CDM). During this process, novel secretion products were discovered, leading to refinement of its genome annotation and metabolic reconstruction. We then used the reconstruction to characterize the metabolic properties of *F. prausnitzii*. Novel carbon sources were proposed and validated *in vitro*. Finally, we propose a functional metabolic map of this important beneficial gut microbe.

MATERIALS AND METHODS

Manual curation of Model SEED draft reconstruction. The *Faecalibacterium prausnitzii* A2-165 genome, consisting of 3,475 protein-coding genes, was retrieved from the Integrated Microbial Genomes–Human Microbiome Project (24) website and imported into the RAST server (25). A draft reconstruction of the microbe was retrieved from the Model SEED pipeline, which is a web-based resource that constructs analysis-ready genome-scale draft metabolic reconstructions based on the genome sequence (26). The draft reconstruction was exported in SBML format and further analyzed using COBRA Toolbox (27) methods.

The content of the draft reconstruction was subsequently manually inspected, curated, validated, and expanded based on a protocol for curation of automated models (26) and established methods in metabolic network reconstruction (23). Similar to our previously described reconstruction approach (28), we manually curated the Model SEED draft reconstruction based on literature and database mining. To streamline the nomenclature used in the draft reconstruction, reaction and metabolite names were translated to BiGG (29) standard identifiers. All reactions, metabolites, and genes included in the draft reconstruction were subsequently inspected and evaluated manually. Reaction directionalities were inspected, and appropriate directionality changes were made based on the BiGG database (29). Gap filling of central pathways was performed and species-specific pathways were filled in manually based on information from the literature. Model predictions were evaluated based on published experimental data. Carbon source utilization predicted by the model was compared with experimental data (11, 13). Furthermore, it was ensured that experimentally observed secretion products (11) could be produced by the model. At this stage of the reconstruction process, the minimal nutrient requirements of *F. prausnitzii* were predicted *in silico* (Fig. 2). A minimal medium composition was defined based on computational predictions and tested experimentally (see the section on laboratory procedures). Furthermore, experiments were performed to test carbon sources for which no experimental data were yet published. Based on the results, a final curation step was performed. The finished, manually curated and validated reconstruction, accounting for 602 genes, was named iFpraus_v1.0.

Figure 1 sums up the applied reconstruction curation and validation pipeline. A detailed description of the manual curation and validation process can be found in the supplemental material. Details on the biomass reaction can also be found in the supplemental material. The content of the final reconstruction iFpraus_v1.0 is presented in spreadsheet format in Table S7 in the supplemental material and is available in SBML format at <http://thielelab.eu>.

Genomic analysis. Comparative genomic identification of transcription factor binding sites and reconstruction of corresponding regulons were performed according to the approach established previously (30), implemented in the RegPredict Web server tool (31). Initial DNA binding site profiles for previously described transcription factors were collected

from the RegPrecise database (32). RNA regulatory elements (riboswitches) were identified using the RibEx tool (33).

***In silico* growth simulations.** Unless stated otherwise, for all simulations with glucose as the carbon source, uptake of glucose was allowed at a rate of 10 mmol g (dry weight)⁻¹ h⁻¹. The uptake rates of other carbon sources were always scaled to the number of carbon atoms with glucose (six carbons) as a reference, e.g., when the glucose uptake rate was 10 mmol g (dry weight)⁻¹ h⁻¹, the uptake rate for lactose (12 carbon atoms) was 5 mmol g (dry weight)⁻¹ h⁻¹.

Gene essentiality in iFpraus_v1.0 was determined using methods implemented in the COBRA Toolbox while simulating growth on glucose minimal medium (see Table S8 in the supplemental material) and rich medium, which consisted of all compounds the model is able to transport. Genes whose deletion resulted in a growth rate of zero were considered essential.

In silico carbon source utilization was tested by simulating minimal medium (see Table S8 in the supplemental material) while omitting glucose and adding the carbon sources one by one.

For simulated YCFAG10 and YCFAG(O₂) media (i.e., medium containing yeast extract, Casitone, and fatty acids and supplemented with 25 mM glucose, and the same medium used to determine oxic growth), glucose uptake was allowed up to an uptake rate of 100 mmol g (dry weight)⁻¹ h⁻¹, and oxygen uptake was allowed up to an uptake rate of 100 mmol g (dry weight)⁻¹ h⁻¹. Yeast extract was assumed to consist of all metabolites included in the yeast reconstruction iMM904 (34) that could also be transported by iFpraus_v0.2. Casitone was assumed to consist of all 20 amino acids. Simulation constraints are listed in Table S9 in the supplemental material.

Constraints used to simulate the expanded defined medium CDM2 are listed in Table S10 in the supplemental material.

Phenotypic phase plane analysis. Phenotypic phase plane analysis was performed as described previously (35). Briefly, fluxes through two exchange reactions representing metabolite uptake or secretion were fixed at different intervals, while biomass production was set as the objective function. For each step, the objective value and the shadow prices for all metabolites in the model were computed and plotted as heat maps. The analysis was performed while minimal medium was simulated (see Table S8 in the supplemental material), with the exception that acetate and carbon source exchange were varied.

Strain used for experimental culture. A stock of *Faecalibacterium prausnitzii* A2-165 DSM 17677, isolated by S. H. Duncan (University of Aberdeen, United Kingdom) was donated to and maintained by H. J. M. Harmsen, Department of Medical Microbiology, University of Groningen, Groningen, The Netherlands.

Growth experiments. *Faecalibacterium prausnitzii* strain A2-165 was grown under anaerobic conditions at 37°C on CDM1, CDM2, and YCFAG medium (see the supplemental material). One or two colonies of *F. prausnitzii* A2-165 grown on YCFAG agar were inoculated into the respective growth medium. Carbon source utilizations were performed by adding filter-sterilized carbon source solutions to YCFA medium. The final concentration of carbon sources in the solution was 1 mg/ml. Growth was confirmed by Gram staining as well as measuring acid production. In both minimal medium and carbon source tests, a decrease in pH value of >0.2 was considered indicative of growth.

Growth curve. A growth curve was plotted for *F. prausnitzii* A2-165 grown on CDM2. Each growth curve represented the average for three biological replicates. Cell numbers were determined with fluorescence *in situ* hybridization (FISH) for samples collected at 0 h, 4 h, 8 h, 12 h, 16 h, 20 h, and 24 h. The FISH was performed with the Cy3-labeled probe Fprau645 (36) as described before (37).

Liquid chromatography-mass spectrometry (LC-MS). Samples for mass spectrometry analysis were taken from the *in vitro* cultures grown in CDM2 described above for the entire length of the experiment (before inoculation and at 4, 8, 12, 16, 20, and 24 h). The results represented the average of three biological replicates.




FIG 1 Schematic overview of the reconstruction assembly, curation, and validation pipeline employed in this study.

An ultra-high-performance liquid chromatography (UPLC) system (UPLC Acquity; Waters, Manchester, United Kingdom) coupled in line with a quadrupole-time of flight hybrid mass spectrometer (Synapt G2; Waters, Manchester, United Kingdom) was used for the analysis of small polar metabolites in spent culture medium as previously reported (38). All materials used in the LC-MS experiments were purchased from Sigma-Aldrich (Germany). All chemicals and solvents were of analytical-grade or higher purity.

A one-way analysis of variance (ANOVA) was used to define measurements presenting a significant change over time ($P < 0.05$ and $P < 0.01$).

Growth medium preparation. The composition of the initial minimal medium, CDM1, was determined by assessing the minimal requirements of the *F. prausnitzii* reconstruction after manual curation based on databases and literature. To determine the composition of a chemically defined medium allowing *F. prausnitzii* to grow, the initial minimal medium was enriched with additional vitamins, amino acids, and bases, resulting in CDM2. CDM1 and CDM2 were prepared as follows: components (the composition is presented in Tables S11 and S12 in the supplemental material) were added to double-distilled H₂O, the final pH value was set to 6.8, and the solutions were filter sterilized. Cysteine (final concentration 1 mg/ml) was used as a reducing agent, while resazurin was added as a redox indicator.

YCFAG medium was prepared as previously reported (11). Before autoclaving, the pH value of the solution was set to 6.5. YCFA medium consisted of the same components as YCFAG medium, except that glucose was omitted, and was prepared in the same way.

RESULTS

We present an approach combining *in silico* and *in vitro* steps to build a high-quality reconstruction of *F. prausnitzii* A2-165 and gain insight into its metabolic potential. A schematic overview of the workflow is presented in Fig. 1.

Generation of a curated draft metabolic reconstruction. A draft metabolic reconstruction for any microbial organism with sequence genome can be obtained using the web-based Model

SEED resource (26). While this resource greatly accelerates the reconstruction process, substantial manual curation of its content is required to ensure accordance between known biochemical and physiological capabilities of the target organism and its *in silico* representation.

The *F. prausnitzii* A2-165 genome, consisting of 3,475 protein-coding genes, was obtained from the Integrated Microbial Genomes-Human Microbiome Project (24) and imported into the RAST server (25). The resulting draft reconstruction, named iFpraus_v0.1, was manually curated, which included inspection of reaction directionalities and gap filling of central pathways and of species-specific pathways based on biochemical information from the available 23 primary research articles. Most importantly, it was ensured that known secretion products (11) and carbon source utilization capabilities (11, 13) were accurately represented. This refined reconstruction was named iFpraus_v0.2 and consisted of 997 reactions across two compartments (extracellular space and cytosol), 818 metabolites, and 585 genes (Table 1). The manual validation and curation process is described in detail in the supplemental material.

An established way of assessing the predictive potential of the models derived from the metabolic reconstructions is the comparison of *in silico* phenotypic traits with experimental data (23). To determine the model's ability to produce known secretion products, biomass production by iFpraus_v0.2 was simulated on YCFAG medium using flux variability analysis. The model predicted that acetate was consumed and butyrate was produced to achieve optimal growth. Formate and D-lactate were produced in some alternate solutions (Table 2). The model thus captured production of *F. prausnitzii*'s major secretion products (11). The calculated growth rate was compared with experimental data col-

TABLE 1 Comparison of automated (iFpraus_v0.1), curated (iFpraus_v0.2), and experimentally validated (iFpraus_v1.0) *F. prausnitzii* A2-165 reconstruction

Feature	iFpraus_v0.1	iFpraus_v0.2	iFpraus_v1.0
No. of:			
Total reactions	820	997	1,030
Metabolic and transport reactions	755	855	873
Exchange and demand reactions	65	142	157
Gene-associated reactions	734	793	807
Compartment-specific metabolites	874	818	833
Genes	598	585	602
% reversible reactions	62.80	39.22	39.13
% irreversible reactions	37.20	60.78	60.87
No. of:			
Blocked reactions	649	220	222
Compartments	2	2	2
Usable carbohydrates as sole carbon sources	3	17 ^a	17 ^a
Produced published/measured secretion products	1	11	17
Ability to produce biomass	No	Yes	Yes

^a See Table S1 in the supplemental material.

TABLE 2 Growth rates and allowed flux spans of secretion products predicted for iFpraus_v0.2 on YCFAG medium^a

Simulation	Prediction on YCFAG medium
Growth rate (h ⁻¹)	0.29
Production (mmol g (dry wt) ⁻¹ h ⁻¹) of:	
Acetate	-16.13 to -8.61
Butyrate	12.82 to 17.13
Formate	0 to 5.03
D-Lactate	0 to 2.51
CO ₂	15.83 to 21.21

^a Constraints for simulated YCFAG medium are listed in Table S9 in the supplemental material. Flux variability analysis (FVA) was carried out with 95% satisfaction of objective required.

lected for *F. prausnitzii* strain A2-165 grown experimentally in rumen fluid-containing minimal medium with 0.2% glucose (M2G medium) with and without acetate in medium (11). Growth on rumen fluid was approximated by simulating YCFAG medium, which consists of acetate, glucose, Casitone, yeast extract, cysteine, minerals, and vitamins. The predicted growth rate was 0.29 h⁻¹ with acetate in the medium and 0.24 h⁻¹ without acetate. The *in vitro* growth rate on rumen fluid-containing M2G medium was 0.32 h⁻¹ with acetate and 0.10 h⁻¹ when acetate was omitted (11). While one cannot directly compare *in silico* and *in vitro* growth rates, as the medium conditions are different, the model captures *F. prausnitzii*'s known trait that acetate supple-

mentation enhances growth (11). Similarly, qualitative carbon source utilization capabilities predicted by the model were compared with experimental data (11, 13) and found to be in agreement (see Table S1 in the supplemental material).

Design of a chemically defined medium using an iterative computational, *in vitro*, and metabolomics approach. *F. prausnitzii* A2-165 is routinely cultivated on YCFAG medium but fails to grow when yeast extract is omitted from the growth medium. Furthermore, the absence of acetate significantly retards growth (11). Hitherto, growth requirements for specific vitamins, cofactors, minerals, and amino acids have not been reported. The metabolic model (iFpraus_v0.2) predicted the inability of *F. prausnitzii* A2-165 to synthesize the amino acids alanine, cysteine, methionine, serine, and tryptophan and the vitamin and cofactors biotin, cobalamin, folic acid, hemin, nicotinic acid or nicotinamide, pantothenic acid, and riboflavin (see Table S2 in the supplemental material). These *in silico* phenotypes were used to define *in vitro* a chemically defined medium (named CDM1); however, *F. prausnitzii* A2-165 was unable to grow on it. CDM1 was supplemented with amino acids, nucleobases, and vitamins (Fig. 2). This modified CDM1, named CDM2, did indeed support the growth of *F. prausnitzii in vitro*. The experimentally determined growth rate was 0.13 h⁻¹, compared to an *in silico* growth rate of 0.26 h⁻¹. An explanation of the higher *in silico* growth rate could be that the applied uptake constraints are higher than the *in vitro* uptakes fluxes.

To optimize the composition of CDM2, the spent CDM2 of *F. prausnitzii* was quantified by LC-MS (38) to reveal consumed and




FIG 2 Description of the overlap between the chemically defined media utilized in this study. Blue circle, compounds included in CDM1 (initial minimal medium proposed by model); orange circle, compounds included in CDM2 (expanded defined medium enabling growth); purple circle, compounds included in CDM3 (final defined medium based on LC-MS data). Green metabolites are those significantly secreted during growth on CDM2; red metabolites are those significantly consumed during growth on CDM2.

secreted metabolite profiles. We found that the concentration of 28 metabolites changed significantly after 20 h growth in CDM2. Of those, 18 were net consumed by *F. prausnitzii*, while 10 were net secreted (see Table S2 in the supplemental material). Six predicted nonessential amino acids were consumed in significant amounts, namely, arginine, histidine, (iso)leucine, lysine, and phenylalanine (note that isoleucine and leucine cannot be distinguished by our LC-MS approach). Of those, only phenylalanine was included in CDM1, and the remaining five may thus be some of the missing components whose absence prevented growth on CDM1. Significant secretion of glutamine and threonine was observed. Furthermore, five amino acids (alanine, cysteine, proline, serine, and valine) were net secreted, but the observed changes were statistically not significant (see Table S2 in the supplemental material). Of the added metabolites in CDM2, 11, including all four added nucleobases, were taken up (Fig. 2; also, see Table S2 in the supplemental material). These findings reveal that CDM2 represents a defined nonminimal medium that enables growth of *F. prausnitzii* *in silico* and *in vitro*.

***F. prausnitzii* consumes and secretes a variety of compounds.** We aimed to identify nonessential metabolites through the consumed and secreted metabolite profiles for growth on CDM2. No growth was observed when adenine and xanthine were removed from the medium. The precise mechanism for this phenotype remained ambiguous, as complete biosynthesis pathways for both bases are annotated in the *F. prausnitzii* A2-165 genome (see Table S3 in the supplemental material). LC-MS analysis revealed a highly significant decrease in adenine ($P = 2.363 \times 10^{-7}$) and a corresponding increase in hypoxanthine ($P = 7.034 \times 10^{-7}$) (see Table S2 in the supplemental material), suggesting that adenine is metabolized via adenine deaminase (FAEPRAA2165_01453 or FAEPRAA2165_01454; EC 3.4.5.2), liberating ammonium ion (Fig. 3). This indicates that adenine serves as an important nitrogen source for these bacteria. Consistently, *in silico* simulations predicted adenine, unlike other nucleobases, as well as ammonium ion to serve as a sole nitrogen source (see Table S2 in the supplemental material).

Furthermore, hemin could be omitted. Hemin biosynthesis is absent (see Table S3 in the supplemental material), and the lack of a requirement suggests that heme-containing proteins may not be encoded by *F. prausnitzii* A2-165. Indeed, we were unable to identify a cytochrome *c* oxidase in its genome (see the supplemental material).

We observed a significant uptake of the vitamins biotin, pantothenic acid, and pyridoxal, confirming the model's predictions that they are essential (see Table S2 in the supplemental material). Cobalamin, folic acid, and riboflavin consumption did not reach significance, although they are predicted to be essential. Riboflavin auxotrophy has been previously demonstrated for *F. prausnitzii* A2-165 (39). Possibly, riboflavin consumption did not reach significance because the vitamin is mainly utilized for an extracellular electron shuttle (39). Thiamine was significantly taken up (see Table S2 in the supplemental material) despite a biosynthesis pathway being annotated in *F. prausnitzii* A2-165. Surprisingly, pyridoxamine was consumed in significant amounts (see Table S2 in the supplemental material). However, no gene for pyridoxamine 5'-phosphate oxidase (EC 1.4.3.5) could be identified in the *F. prausnitzii* A2-165 genome, which is a prerequisite for pyridoxamine utilization.

A statistically significant net secretion of *p*-aminobenzoic acid

in the medium was observed between 0 and 4 h, while a decrease occurred between 4 and 20 h, suggesting that *F. prausnitzii* may be able to utilize or synthesize *p*-aminobenzoic acid. However, we could not identify the *p*-aminobenzoic acid biosynthesis pathway in the genome (see Table S2 in the supplemental material), in line with previous results that *F. prausnitzii* M21/2 does not possess the complete folate biosynthesis pathway (40).

Finally, *F. prausnitzii* secreted five previously unreported metabolites (see Table S2 in the supplemental material), namely, dihydroorotic acid, *N*-acetylglutamic acid, *N*-acetylaspargic acid, and 3-methyl-2-oxovaleric acid, as well as phenyllactic acid, which has already been shown to be produced by *F. prausnitzii* strains M21/2 and SL3/3 (41).

We then aimed to refine CDM2. Glutamine and threonine could be omitted from CDM2, in line with model predictions that *F. prausnitzii* A2-165 is prototrophic for these amino acids. Pyridoxamine and *p*-aminobenzoic acid could further be omitted, confirming that pyridoxal is a sufficient source of vitamin B₆ but pyridoxamine may be unusable. Furthermore, guanine, uracil, and orotic acid could be omitted. Biosynthesis pathways for uracil, guanine, and orotic acid are completely annotated in *F. prausnitzii* A2-165, confirming that these growth components are nonessential. Deletion of these three compounds from CDM2 resulted in poor and unreliable growth, however. We conclude that *F. prausnitzii*'s growth is unstable in noncomplex media, possibly due to low nutrient concentrations.

The composition of the more refined form of CDM2, named CDM3, which allows growth, though poor and unreliable, of *F. prausnitzii* *in vitro* is shown in Fig. 2.

Exometabolomic data guide the refinement of *F. prausnitzii*'s genome annotation. Uptake of six vitamins was observed, for which the current annotation for *F. prausnitzii* A2-165 in NCBI Protein, The Seed, IMG, and BioCyc does not include transporters (see Table S3 in the supplemental material). Using comparative genomics analysis, we identified energy-coupling factor (ECF) family transporters for biotin, folic acid, pyridoxine, pantothenic acid, riboflavin, and thiamine in the *F. prausnitzii* A2-165 genome, supporting the idea that these vitamins can be consumed (Table 3). All transporters require shared *ecfAAT* energizing components (encoded by FAEPRAA2165_02788-02790), which are energy-coupling modules required for substrate binding that include the components *EcfA*, *EcfA'*, and *EcfT* (42). Furthermore, a currently unannotated pyridoxine-responsive regulon, corresponding to PdxR (FAEPRAA2165_02613), and a niacin-responsive regulon, corresponding to NiaR (FAEPRAA2165_01816), which regulate the associated ECF transporters, were identified. Some of the transporter-encoding genes mentioned are currently mis- or unannotated (Table 3).

Furthermore, we aimed to confirm the presence of functional biosynthesis pathways and transporters for amino acids not present in CDM1 that were consumed in significant amounts. We newly identified a histidine regulon, corresponding to HisR (FAEPRAA2165_01654), which regulates the histidine biosynthesis operon *hisGD1DCBHAFEJ* (FAEPRAA 2165_00489-480), a T-box regulon, *leuABCD*, for leucine (FAEPRAA2165_01127-31), and *ilvD* for isoleucine (FAEPRAA 2165_00371) (Table 3). We confirmed the presence of an arginine regulon containing the arginine biosynthesis operon *argGHCJBDF* (FAEPRAA2165_00172-163), *argF* (FAEPRAA2165_00366), and newly identified a predicted major facilitator superfamily (MFS)-




FIG 3 Overview of proposed pathways in *F. prausnitzii* A2-165 based on genome annotation, the exometabolome, and growth experiments. Putative pathways for which no gene annotation could be identified, as well as substrates known to be transported but for which transporter gene annotations are unknown, are indicated with a question mark. Transporter mechanisms are indicated by icons (see the key).

TABLE 3 Proposed improvements and specifications to the genome annotation of *F. prausnitzii* A2-165

NCBI Protein ID	Current annotation (NCBI) ^a	Proposed annotation
FAEPRAA2165_01205	Hypothetical protein	Pantothenate transporter gene <i>panT</i>
FAEPRAA2165_01298	Hypothetical protein	Riboflavin transporter gene <i>ribU</i>
FAEPRAA2165_01333	Putative proton-coupled thiamine transporter YuaJ	Thiamine transporter gene <i>thiT</i>
FAEPRAA2165_01388	4-Phosphoerythronate dehydrogenase	D-Lactate dehydrogenase
FAEPRAA2165_01654	TrpR family protein YerC/YecD	Histidine repressor HisR
FAEPRAA2165_01745	ABC transporter substrate binding protein	Tryptophan ABC transporter gene <i>trpX</i>
FAEPRAA2165_01747	Branched-chain amino acid ABC transporter, permease protein	Tryptophan ABC transporter gene <i>trpY</i>
FAEPRAA2165_01748	ABC transporter, ATP-binding protein	Tryptophan ABC transporter gene <i>trpZ</i>
FAEPRAA2165_01816	3H domain protein	Niacin-responsive regulator NiaR
FAEPRAA2165_01935	Dehydrogenase, FMN dependent	Hydroxyacid oxidase gene (similar to eukaryotic gene <i>Hao2</i>)
FAEPRAA2165_02602	Hypothetical protein	Niacin transporter gene <i>niaY</i>
FAEPRAA2165_02613	Transcriptional regulator, GntR family	Pyridoxine-responsive regulator PdxR
FAEPRAA2165_02615	Hypothetical protein	ECF-family pyridoxine transporter gene <i>pxdT</i>
FAEPRAA2165_02750	Transporter, major facilitator family protein	MFS-type arginine transporter
FAEPRAA2165_02761	Glycosyl hydrolase family 32	Beta-fructosidase (levanase/invertase) gene
FAEPRAA2165_02762	Tat pathway signal sequence domain protein	Fructooligosaccharide ABC transporter
FAEPRAA2165_02763	ABC transporter, permease protein	Fructooligosaccharide ABC transporter
FAEPRAA2165_02764	ABC transporter, permease protein	Fructooligosaccharide ABC transporter
FAEPRAA2165_02765	Transcriptional regulator, LacI family	Fructooligosaccharides utilization transcriptional regulator SusR, LacI family
FAEPRAA2165_02788	Cobalt transport protein	EcfT energizing component
FAEPRAA2165_02789	ABC transporter, ATP-binding protein	EcfA' energizing component
FAEPRAA2165_02790	Cobalt ABC transporter, ATP-binding protein	EcfA energizing component
FAEPRAA2165_03014	Hypothetical protein	Folate transporter gene <i>folT</i>
FAEPRAA2165_03033	NlpA lipoprotein	Predicted methionine ABC transporter gene <i>metQ</i>
FAEPRAA2165_03034	ABC transporter, ATP-binding protein	Predicted methionine ABC transporter gene <i>metP</i>
FAEPRAA2165_03035	ABC transporter, permease protein	Predicted methionine ABC transporter gene <i>metN</i>
FAEPRAA2165_03085	ABC transporter, substrate-binding protein, family 3	Lysine ABC transporter gene <i>lysX</i>
FAEPRAA2165_03087	ABC transporter, permease protein	Lysine ABC transporter gene <i>lysY</i>
FAEPRAA2165_03088	ABC transporter, permease protein	Lysine ABC transporter gene <i>lysZ</i>
FAEPRAA2165_03374	ABC transporter, ATP-binding protein	Histidine ABC transporter gene <i>hisZ</i>
FAEPRAA2165_03375	ABC transporter, permease protein	Histidine ABC transporter gene <i>hisY</i>
FAEPRAA2165_03376	ABC transporter, substrate-binding protein, family 3	Histidine ABC transporter gene <i>hisX</i>

^a FMN, flavin mononucleotide.

type arginine transporter (FAEPRAA2165_02750). Histidine, arginine, leucine, and isoleucine biosynthesis is thus most likely functional in *F. prausnitzii* A2-165. We further identified ABC-type transporters for histidine (*hisXYZ*; FAEPRAA2165_03376-74), lysine (*lysXYZ*; FAEPRAA2165_03085-88), methionine (*metQPN*; FAEPRAA2165_03033-35), and tryptophan (*trpXYZ*; FAEPRAA2165_01745-48) that are controlled by a lysine riboswitch and amino acid-specific T boxes. Finally, we identified a previously misannotated D-lactate dehydrogenase and a putative hydroxyacid oxidase (Table 3; also, see the supplemental material).

In summary, several biomass precursor transporters included in the corresponding biosynthesis regulons were identified, and 33 novel gene annotations for *F. prausnitzii* A2-165 were proposed. In particular, we identified the transported substrates for transporters with currently generic annotations (Table 3).

Reconstruction content, refinement, and characteristics. iFpraus_v0.2 was consequently refined. Missing transport reactions for all metabolites observed to be consumed or secreted were added, and the corresponding transporter-including genes (Table 3) were assigned accordingly. Reactions consuming or producing the metabolites were included as necessary to connect the metabolites to the network if supporting gene annotations could be identified (Table 3; also, see the supplemental material). In total, 37 reactions, 15 nonunique metabolites, and 17 genes were added,

and six reactions were replaced during the refinement based on exometabolome measurements (for details, see the supplemental material and see Table S2 in the supplemental material). The resulting final reconstruction was named iFpraus_v1.0, accounting for 602 genes, 1,030 reactions, and 833 metabolites, with a final average confidence score of 2.29 (see the supplemental material) and a genome coverage of 17%. Excluding exchange and demand reactions, only 66 of all 1,030 reactions are not supported by genome annotation. iFpraus_v1.0 is able to utilize carbon sources and produce secretion products in good agreement with literature and our *in vitro* experiments (see Tables S1 and S4 in the supplemental material). The expansion of the reconstruction resulted in only minor changes in growth rate and secretion product predictions (data not shown).

At its end, this integrated systems biology approach yielded a metabolic chart of *F. prausnitzii* summarizing its metabolic capabilities and connections with the environment (Fig. 2). Our proposed refinements to *F. prausnitzii*'s genome annotation are summed up in Table 3. A comparison of proposed function, NCBI Protein, IMG, BioCyc, and The Seed gene annotations for all genes included in the reconstruction is listed in Table S3 in the supplemental material.

The subsystem participation of reactions in iFpraus_v1.0 was analyzed and compared with that of the previously assembled *Bac-*




FIG 4 Comparison of subsystem participation in the *F. prausnitzii* A2-165 reconstruction iFpraus_v1.0 and the *B. thetaiotaomicron* VPI-5482 reconstruction iAH991. (a) Reactions; (b) genes.

teroides thetaiotaomicron strain VPI 5482 reconstruction iAH991 (28) (Fig. 4). As expected, the most striking difference between the two reconstructions is the percentage of reactions and genes involved in polysaccharide degradation, which make up 9% and 26%, respectively, in the *B. thetaiotaomicron* reconstruction but only 2% in *F. prausnitzii* (Fig. 4). This difference reflects the significantly higher saccharolytic potential of *B. thetaiotaomicron*, in line with observations that *B. thetaiotaomicron* possesses 255 glycoside hydrolases and 29 polysaccharide lyases, while the *F. prausnitzii* genome encodes only 17 glycoside hydrolases and one polysaccharide lyase (43). Moreover, 61% of *B. thetaiotaomicron*'s glycosylhydrolases are noncytosolic (44), while *F. prausnitzii* possesses mainly cytosolic enzymes. Accordingly, 22% of the genes in the *F. prausnitzii* reconstruction but only 8% of the genes in the *B. thetaiotaomicron* reconstruction are involved in transport (Fig. 4b), in line with the fact that firmicutes possesses a number of phosphotransferase systems (PTS) for efficient nutrient uptake while *B. thetaiotaomicron* has no genes encoding PTS (45).

Prospective use of the metabolic reconstruction: assessing the metabolic capability of *F. prausnitzii* in silico and in vitro.

(i) **Insights into the central metabolism of *F. prausnitzii*.** Network analysis revealed the central carbon metabolism of *F. prausnitzii* (Fig. 3). Glucose and most other carbon sources are metabolized via glycolysis. Amino sugars enter metabolism via the amino sugar pathway with fructose-6-phosphate as the product, while uronic acids are converted to pyruvate and glyceraldehyde-3-phosphate via pentose and glucuronate interconversions. Formate is produced via pyruvate formate lyase and can be further converted to CO₂ by formate dehydrogenase. The citric acid cycle is incomplete, as malate dehydrogenase (EC 1.1.1.37) and oxoglutarate dehydrogenase (EC 1.2.4.2) are not annotated. However, the steps for conversion of succinate to malate and oxaloacetate to

2-oxoglutarate are present, in agreement with the observation that malate and succinate are formed from fumarate (39). Finally, an incomplete pentose phosphate pathway is annotated in the *F. prausnitzii* A2-165 genome that does not allow the microbe to generate NADPH via the pentose phosphate pathway. However, the necessary enzymes for synthesis of erythrose-4-phosphate as precursors for synthesis of aromatic amino acids and 5-phosphoribosyl-1-pyrophosphate (PRPP), which is required for synthesis of purines and pyrimidines, are accounted for (Fig. 3).

(ii) **Acetate supplementation increases energy harvest from glucose.** We investigated *in silico* how acetate consumption enables *F. prausnitzii* to harvest more energy from carbon sources. Using flux balance analysis (46) while minimizing internal flux, we calculated the predicted ATP yield per mmol glucose, without and with acetate present in the *in silico* medium. The predicted ATP yields were 2 and 3, respectively. Flux balance analysis revealed that, in the absence of acetate, glucose was fermented to D-lactate and ATP was produced via phosphoenolpyruvate carboxykinase (BiGG ID: PPCKr) (see Fig. S3a in the supplemental material). When acetate uptake was allowed, the model switched from D-lactate to butyrate and CO₂ production, leading to proton transport to the extracellular compartment via NADH:ferredoxin oxidoreductase (BiGG ID: FDNADOX_H). This proton motive force enabled ATP production via ATP synthase (BiGG ID: ATPS4) (see Fig. S3a in the supplemental material), thus allowing more efficient utilization of glucose. The predicted flux ratio between ATP synthesis and acetate uptake was 1:2; hence, 1 mmol g (dry weight)⁻¹h⁻¹ ATP per 2 mmol g (dry weight)⁻¹h⁻¹ acetate was produced.

(iii) **Metabolic modeling reveals novel carbon sources.** Using flux balance analysis, novel carbon sources were predicted. iFpraus_v1.0 has exchange reactions defined for 154 unique me-

TABLE 4 Previously undescribed carbon source utilization predicted for iFpraus_v1.0 (*F. prausnitzii* A2-165) and experimental validation

Carbon source	Relative <i>in silico</i> growth rate (h ⁻¹)	<i>In vivo</i> growth
Arbutin	No growth	No growth
Citrate	No growth	No growth
Fumarate	No growth	No growth
Inosine	0.66	Weak acid production
Lactose	0.78	Growth
Malate	0.07	No growth
Mannose	No growth	No growth
<i>N</i> -Acetylneuraminic acid	0.98	Growth
Salicin	No growth	No growth
Succinate	No growth	No growth

^a Relative *in silico* growth was calculated with the predicted growth rate on glucose as a reference. A pH decrease of >0.2 was considered indicative of growth *in vitro*.

tabolites, of which 90 contain carbons. We supplemented the *in silico* YCFA medium with each of these candidate carbon sources and found that 17 of 90 indeed supported growth *in silico*, including 14 known sole carbon sources (11, 13) (see Table S1 in the supplemental material) as well as lactose, inosine, and the host-derived monosaccharide *N*-acetylneuraminic acid. The utilization pathways for these three novel substrates are supported by the genome annotation (for details, see the supplemental material). Furthermore, very poor growth on malate was predicted. Unusable sole carbon sources included all amino acids and dipeptides (see Table S1 in the supplemental material), consistent with reports that *F. prausnitzii* has little or no ability to utilize peptides (13).

We validated 10 of these predictions in *in vitro* cell culture (Table 4). As predicted *in silico*, *F. prausnitzii* A2-165 grew on lactose and *N*-acetylneuraminic acid, confirmed by acid production. On inosine, acid production was detectable but weak, and the difference in pH value did not reach 0.2. *F. prausnitzii* A2-165 is thus able to utilize inosine as a carbon source, but to an extent that may not be sufficient for growth if no other usable carbon source is provided. Furthermore, recent experimental evidence suggested that fumarate can serve as a carbon source (39). The model predicted that *F. prausnitzii* A2-165 could utilize fumarate as an additional, though not as the sole, carbon source. Our *in vitro* experiments agreed with this prediction (Table 4). Furthermore, *F. prausnitzii* A2-165 did not grow on malate, for which poor growth was predicted (Table 4). Both compounds likely fail to sustain growth as sole carbon sources due to the loss of one carbon atom when malate is converted to pyruvate via fumarase (BiGG ID: FUM; FAEPRAA2165_03471-03472) and malic enzyme (BiGG ID: ME1; FAEPRAA2165_03473). Moreover, in agreement with model predictions, *F. prausnitzii* A2-165 was also unable to grow on arbutin, citrate, mannose, salicin, and succinate (Table 4).

Taken together, these data indicate that *F. prausnitzii*'s genome encodes numerous transporters and the microorganism is also able to utilize many host- and diet-derived metabolites for energy and biomass production.

(iv) Utilization of oxygen benefits *F. prausnitzii*. Recently, it was shown that *F. prausnitzii* utilizes oxygen or fumarate as electron acceptors for an extracellular electron shuttle involving cysteine or glutathione and riboflavin (39). Using flux balance anal-

ysis, we investigated how the addition of oxygen to the *in silico* YCFAG medium benefits the microbe and changes pathway utilization by *F. prausnitzii*. Therefore, we modeled two conditions, anoxic growth in YCFAG medium with glucose (YCFAG10 medium) and oxic growth in YCFAG medium with glucose [YCFAG(O₂) medium], after experimental conditions (39) and predicted molar yields for secretion products and biomass (see Table S5 in the supplemental material).

We inspected the pathway usage for the two conditions. Flux through the reactions representing the extracellular electron shuttle (BiGG IDs: ESHCYS_FPe, ESHCYS2_FPe, ESHGLU_FPe, and ESHGLU2_FPe) was enabled for YCFAG(O₂) but not for YCFAG10 (see Fig. S3b in the supplemental material), confirming that the model correctly captured the recently discovered electron shuttle. Furthermore, oxygen consumption increased the *in silico* growth rate by 30% (see Table S5 in the supplemental material). Flux balance analysis revealed that flux through a flavin reductase (BiGG ID: FLVRxe; FAEPRAA2165_00362), which regenerates NAD⁺ from NADH (see Fig. S3b in the supplemental material), increased 15-fold under the YCFAG(O₂) condition. In contrast, if no flux through FLVRxe was allowed, oxygen uptake could no longer increase the *in silico* growth rate (see Table S6 in the supplemental material), demonstrating that this reaction is indeed responsible for the predicted growth stimulation by oxygen. We thus propose that the uptake of oxygen leads to a higher flux through the extracellular electron shuttle and through the stoichiometrically coupled flavin reductase, which subsequently moves the NAD⁺/NADH ratio in a favorable direction, leading to an increase in growth yield. The model predicted acetate production rather than consumption on YCFAG(O₂) medium (see Table S5 in the supplemental material). In contrast, acetate consumption was observed *in vitro* on YCFAG(O₂) medium (39). Due to NAD⁺ being regenerated mainly via flavin reductase, flux through butyrate fermentation pathway, which also converts NADH to NAD⁺, was not enforced at optimal growth yield, and acetyl-CoA was mainly converted to acetate. The reason for this discrepancy with *in vitro* results may be explained by missing regulatory constraints in the model or incomplete knowledge about the molecular composition of the yeast extract present in the *in vitro* YCFAG medium.

(v) Phenotypic phase plane analysis predicts growth-limiting nutrients. The effect of secretion product ratio on growth rate was predicted using phenotypic phase plane (PhPP) analysis. Briefly, in the PhPP analysis, two constraining environmental variables (e.g., flux through exchange reactions) are varied, while a third parameter (e.g., biomass production) is optimized. The analysis may reveal different regions, or “phases,” in the resulting phenotypic phase plane representing qualitatively different pathway utilizations. These phases are computed based on shadow prices. A metabolite's shadow price represents the extent to which increasing the flux through the metabolite would increase flux through the particular objective function. By definition, a positive shadow price indicates that increasing the flux through this metabolite would increase the objective function flux, while a negative shadow price represents an associated decrease in objective function flux (35). Using PhPP analysis, we computed the effect of varying carbon source uptake and acetate exchange on growth rate (Fig. 5). Furthermore, the shadow prices for all metabolites, excluding dead-end metabolites, were calculated.

Glucose and galacturonic acid uptake were varied against ace-




FIG 5 Phenotypic phase plane analysis performed for the *F. prausnitzii* A2-165 reconstruction iFpraus_v1.0. Growth rates and shadow prices were plotted as heat maps spanning the feasible solution space. (a) Glucose uptake varied against acetate exchange, plotted in three-dimensional (3D) and 2D format. (b) Galacturonic acid uptake varied against acetate exchange, plotted in 3D and 2D format.

tate exchange. The analysis revealed different phenotypic phases. As expected, increasing carbon source uptake flux increased growth rate (Fig. 5). When comparing the point of minimal carbon source uptake rate that still allowed optimal growth (indicated by a star in Fig. 5a and b), it was observed that for glucose, acetate had to be consumed, while for galacturonic acid, acetate had to be produced. The maximally achievable growth rate was equal for both carbon sources. Forcing acetate production thus limited growth on glucose, while on galacturonic acid, the growth yield decreased with increasing acetate consumption. This difference can be explained by their distinct metabolisms. Glucose is fully metabolized via glycolysis, yielding 2 mol of pyruvate per mol. Uronic acids are utilized via pentose and glucuronate interconversions, resulting in 1 mol of glyceraldehyde-3-phosphate and 1 mol of pyruvate per mol (Fig. 3). The reduced flux through glycolysis during growth on uronic acids results in a lower NADH yield per mol of carbon source. Thus, ATP gain via acetate kinase becomes preferable to the NADH-consuming butyrate pathway.

We then examined the shadow prices for the entire phase plane while varying glucose against acetate uptake (see Fig. S4 in the supplemental material). We found that at low glucose uptake rates, the model was carbon limited, as indicated by positive

shadow prices for glucose and other usable carbon sources. At optimal growth, however, growth was limited by NAD^+ , NADP^+ , ATP, acetyl coenzyme A (acetyl-CoA), amino acids, and cell envelope biosynthesis building blocks. Thus, reducing equivalent availability and energy levels rather than carbon skeleton availability, as well as cost-intensive biomass precursors, is growth limiting in this phase. Furthermore, cost-intensive biomass precursors involved in fatty acid metabolism, e.g., hexadecanoic acid, switched from a positive shadow price at suboptimal growth to a negative shadow price at optimal growth. Increasing the availability of hexadecanoic acid at suboptimal growth would thus save biosynthesis costs, while at optimal growth, the metabolite would be in excess and costly to remove. Shadow price analysis thus predicts how the limited resources need to be distributed in *F. prausnitzii* to achieve optimal growth.

DISCUSSION

In this work, we manually constructed and validated a metabolic reconstruction of *Faecalibacterium prausnitzii* A2-165 starting from an automated draft reconstruction. A defined medium enabling growth of the microbe was developed. Previously proposed traits of the microbe, such as generation of a proton motive force,

were captured via metabolic modeling. The model was then successfully applied to predict novel carbon source utilization capabilities, which were validated experimentally. Finally, a phenotypic phase plane analysis predicted optimal ratios between acetate exchange and carbon source uptake, as well as growth-limiting metabolites.

We, and others, have previously shown that automatically generated GENREs, based solely on genome annotation, do not adequately capture biochemical characteristics and phenotypic properties of the target organisms (28, 47, 48). However, as poorly characterized organisms have a limited amount of published biochemical data available, a key ingredient for traditional reconstruction of high-quality metabolic reconstructions (23), the genome becomes the main source of metabolic information. Here, we demonstrated that the draft reconstruction in conjunction with *in vitro* experiments and metabolomic measurements could greatly augment the biochemical knowledge about the target organism. In fact, we propose a comprehensive metabolic map for *F. prausnitzii* (Fig. 3), which summarizes all its measured, annotated, and predicted metabolic capabilities. While the reconstruction captures qualitative properties well, the predicted formate production rates relative to the butyrate production rates were too low (Table 2). This discrepancy may be due to missing regulatory or kinetic constraints. Butyrate and formate production varies drastically between the different *F. prausnitzii* strains (11), despite their having the same central fermentation pathways encoded in the genomes. In fact, inclusion of nonmetabolic cellular processes, such as regulation and macromolecular synthesis, with metabolic models has been shown to increase their predictive potential by reducing the set of feasible solutions significantly (49–53).

Guided by the refined metabolic reconstruction, we then developed an initial medium, CDM1, which was further improved through the analysis of metabolomic data. CDM2 enabled growth of *F. prausnitzii* A2-165, in contrast to CDM1, while not being minimal. The medium should prove useful, as it enables cultivation of *F. prausnitzii* A2-165 under defined nutrient concentrations. Growth on CDM2 (0.13 h^{-1}) is poorer than on YCFAG medium (0.55 h^{-1}) (62). However, *F. prausnitzii* is generally difficult to cultivate, and its growth is likely influenced by factors other than medium composition.

It has been proposed that the conversion of acetate to butyrate by colonic bacteria leads to further energy gains for the bacteria in the form of ATP by means of a proton motive force (10). Correspondingly, the model predicted the generation of one additional molecule of ATP per two consumed molecules of acetate via such a proton motive force. This ratio may be validated experimentally in future efforts. Furthermore, it has been shown that extracellular riboflavin drives an extracellular electron shuttle with oxygen as the terminal electron acceptor (54). In line with this observation, we predicted an increase in growth rate in the presence of oxygen due to a riboflavin-utilizing flavin reductase (FAEPRAA2_165_00362), which may be a valuable target for further analysis. Moreover, we could not observe significant changes in riboflavin medium concentration, suggesting that the vitamin is utilized extracellularly (see Table S2 in the supplemental material). Riboflavin may be an important factor benefitting *F. prausnitzii*. It has been proposed that a diet rich in riboflavin may promote

the abundance of the beneficial faecalibacteria in the human gut (39, 54).

We furthermore predicted and confirmed lactose and *N*-acetylneuraminic acid utilization by *F. prausnitzii* A2-165. *N*-Acetylneuraminic acid (sialic acid) is an amino sugar found in human mucus and thus extensively present in the human intestine. *N*-Acetylneuraminic acid utilization confers a competitive advantage to several pathogens and opportunistic pathogens colonizing the gut, including *Salmonella enterica*, *Bacteroides fragilis*, and enterohemorrhagic *Escherichia coli*. *F. prausnitzii* is one of few human gut commensals possessing the sialic acid utilization gene cluster (55). The microbe's ability to utilize sialic acid may be beneficial for the host if it can successfully outcompete pathogens in mucus-rich environments. The reconstruction further captures the fact that sialic acid can also serve as nitrogen source (55) (see Table S2 in the supplemental material).

Finally, a phenotypic phase plane analysis identified optimal ratios between carbon source uptake and acetate exchange, as well as growth-limiting nutrients that may represent bottlenecks. Maximal growth was limited not by the availability of carbon skeletons but by that of other biomass precursors, such as cost-intensive amino acids and cell envelope building blocks. The model was further predicted to be nitrogen source limited at optimal growth (see the supplemental material). *F. prausnitzii* might thus benefit from growth on carbon sources that are also nitrogen sources. Correspondingly, increasing the availability of *N*-acetylglucosamine but not of glucose was predicted to enhance growth at optimal carbon source-to-acetate exchange ratios (see Fig. S4 in the supplemental material). In agreement with this prediction, *F. prausnitzii* A2-165 grew better on *N*-acetylglucosamine than on glucose (13). The analysis further suggested that resources need to be distributed optimally to enable optimal growth. Investing resources in metabolites that do not contribute to biomass production was predicted to lower the growth rate.

Another metabolic reconstruction of *F. prausnitzii* A2-165, iFap484, was recently published (56). However, unlike iFpraus_v1.0, which was experimentally validated and refined based on exometabolomic data, iFap484 was constructed solely based on the limited available bibliome for *F. prausnitzii* A2-165. Furthermore, iFpraus_v1.0 accounts for 118 genes and 317 reactions more and thus has a significantly higher pathway coverage than iFap484.

The potential of systems biology to study both host-microbe and microbe-microbe interactions for microbes relevant to human health is promising (16, 57). An interesting prospective application is the construction of an *in silico* ex-germfree mouse model. Germfree animals selectively colonized with representative gut microbes are well-established model organisms (58). Experimental data, e.g., *in vivo* studies on ex-germfree animals colonized with a *Bacteroidetes* and a *Firmicutes* representative (59), including a recent study in which germfree rats were colonized selectively with *F. prausnitzii* and *B. thetaiotaomicron* (60), could thus be put in context. Furthermore, it has been proposed that increasing the abundance of beneficial faecalibacteria in the gut might have therapeutic potential and contribute to intestinal homeostasis (5). Using *F. prausnitzii* as a probiotic, however, would require ensuring its survival until its arrival in the colon (5). Using metabolic modeling, formulations that improve the survival of *F. prausnitzii* in the upper intestinal tract, and prebiotics that increase its abundance in the gut, could be predicted.

Finally, the approach presented here can be readily applied to

other uncharacterized gut bacteria. This includes yet-undiscovered potential “keystone” species, which specialize in important functions found only in a selected few microbes (61). The human gut is populated by an estimated 1,000 species (2), most of which have not been characterized. Recent technological advances permit isolation and characterization of microbes from natural microbiota, but their cultivation and phenotypic characterization may be hampered by a lack of appropriate medium availability. Our proposed iterative approach using metabolic reconstruction and metabolomic methods can fill this gap. Performing multiple iterations of computation and experiments could result in the identification of a minimal medium for the target organism.

ACKNOWLEDGMENTS

We thank S. Valgeirsdóttir for assisting with the sample preparation for the LC-MS analysis and D. Ravchev for help with the genomic analysis. We also thank R. M. T. Fleming for valuable discussions.

This work was supported by a Marie Curie International Reintegration grant 19 to I.T. (no. 249261) within the 7th European Community Framework Program and by an ATTRACT program grant to I.T. (FNR/A12/01) from the Luxembourg National Research Fund (FNR).

REFERENCES

- Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. 2005. Diversity of the human intestinal microbial flora. *Science* 308:1635–1638. <http://dx.doi.org/10.1126/science.1110591>.
- Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Meta HITC, Bork P, Ehrlich SD, Wang J. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464:59–65. <http://dx.doi.org/10.1038/nature08821>.
- NIH HMP Working Group, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M. 2009. The NIH Human Microbiome Project. *Genome Res.* 19:2317–2323. <http://dx.doi.org/10.1101/gr.096651.109>.
- Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze XL, Brown D, Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley GE, Parkhill J, Flint HJ. 2011. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. *ISME J.* 5:220–230. <http://dx.doi.org/10.1038/ismej.2010.118>.
- Miquel S, Martin R, Rossi O, Bermudez-Humaran L, Chatel J, Sokol H, Thomas M, Wells J, Langella P. 2013. *Faecalibacterium prausnitzii* and human intestinal health. *Curr. Opin. Microbiol.* 16:255–261. <http://dx.doi.org/10.1016/j.mib.2013.06.003>.
- Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. 2012. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* 490:55–60. <http://dx.doi.org/10.1038/nature11450>.
- Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F. 2013. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* 498:99–103. <http://dx.doi.org/10.1038/nature12198>.
- Tremaroli V, Backhed F. 2012. Functional interactions between the gut microbiota and host metabolism. *Nature* 489:242–249. <http://dx.doi.org/10.1038/nature11552>.
- Sokol H, Pigneur B, Watterlot L, Lakhari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P. 2008. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc. Natl. Acad. Sci. U. S. A.* 105:16731–16736. <http://dx.doi.org/10.1073/pnas.0804812105>.
- Louis P, Flint HJ. 2009. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS Microbiol. Lett.* 294:1–8. <http://dx.doi.org/10.1111/j.1574-6968.2009.01514.x>.
- Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ. 2002. Growth requirements and fermentation products of *Fusobacterium prausnitzii*, and a proposal to reclassify it as *Faecalibacterium prausnitzii* gen. nov., comb. nov. *Int. J. Syst. Evol. Microbiol.* 52:2141–2146. <http://dx.doi.org/10.1099/ijs.0.02241-0>.
- Miquel S, Martin R, Bridonneau C, Robert V, Sokol H, Bermudez-Humaran LG, Thomas M, Langella P. 2014. Ecology and metabolism of the beneficial intestinal commensal bacterium. *Gut Microbes* 5:146–151. <http://dx.doi.org/10.4161/gmic.27651>.
- Lopez-Siles M, Khan TM, Duncan SH, Harmsen HJ, Garcia-Gil LJ, Flint HJ. 2012. Cultured representatives of two major phylogroups of human colonic *Faecalibacterium prausnitzii* can utilize pectin, uronic acids, and host-derived substrates for growth. *Appl. Environ. Microbiol.* 78:420–428. <http://dx.doi.org/10.1128/AEM.06858-11>.
- Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. 2009. Effect of inulin on the human gut microbiota: stimulation of *Bifidobacterium adolescentis* and *Faecalibacterium prausnitzii*. *Br. J. Nutr.* 101:541–550. <http://dx.doi.org/10.1017/S0007114508019880>.
- Kim TY, Sohn SB, Kim YB, Kim WJ, Lee SY. 2012. Recent advances in reconstruction and applications of genome-scale metabolic models. *Curr. Opin. Biotechnol.* 23:617–623. <http://dx.doi.org/10.1016/j.copbio.2011.10.007>.
- Thiele I, Heinken A, Fleming RM. 2013. A systems biology approach to studying the role of microbes in human health. *Curr. Opin. Biotechnol.* 24:4–12. <http://dx.doi.org/10.1016/j.copbio.2012.10.001>.
- Mahadevan R, Bond DR, Butler JE, Esteve-Nunez A, Coppi MV, Palsson BO, Schilling CH, Lovley DR. 2006. Characterization of metabolism in the Fe(III)-reducing organism *Geobacter sulfurreducens* by constraint-based modeling. *Appl. Environ. Microbiol.* 72:1558–1568. <http://dx.doi.org/10.1128/AEM.72.2.1558-1568.2006>.
- Chang RL, Ghamari L, Manichaikul A, Hom EF, Balaji S, Fu W, Shen Y, Hao T, Palsson BO, Salehi-Ashtiani K, Papin JA. 2011. Metabolic network reconstruction of *Chlamydomonas* offers insight into light-driven algal metabolism. *Mol. Syst. Biol.* 7:518. <http://dx.doi.org/10.1038/msb.2011.52>.
- Wodke JA, Puchalka J, Lluich-Senar M, Marcos J, Yus E, Godinho M, Gutierrez-Gallego R, dos Santos VA, Serrano L, Klipp E, Maier T. 2013. Dissecting the energy metabolism in *Mycoplasma pneumoniae* through genome-scale metabolic modeling. *Mol. Syst. Biol.* 9:653. <http://dx.doi.org/10.1038/msb.2013.6>.
- Oliveira AP, Nielsen J, Forster J. 2005. Modeling *Lactococcus lactis* using a genome-scale flux model. *BMC Microbiol.* 5:39. <http://dx.doi.org/10.1186/1471-2180-5-39>.
- Chavali AK, Whittmore JD, Eddy JA, Williams KT, Papin JA. 2008. Systems analysis of metabolism in the pathogenic trypanosomatid *Leishmania major*. *Mol. Syst. Biol.* 4:177. <http://dx.doi.org/10.1038/msb.2008.15>.
- Baart GJ, Zomer B, de Haan A, van der Pol LA, Beuvery EC, Tramper J, Martens DE. 2007. Modeling *Neisseria meningitidis* metabolism: from genome to metabolic fluxes. *Genome Biol.* 8:R136. <http://dx.doi.org/10.1186/gb-2007-8-7-r136>.
- Thiele I, Palsson BO. 2010. A protocol for generating a high-quality genome-scale metabolic reconstruction. *Nat. Protoc.* 5:93–121. <http://dx.doi.org/10.1038/nprot.2009.203>.
- Markowitz VM, Chen IM, Palaniappan K, Chu K, Szeto E, Grechkin Y, Ratner A, Jacob B, Huang J, Williams P, Huntemann M, Anderson I, Mavromatis K, Ivanova NN, Kyrpides NC. 2012. IMG: the Integrated Microbial Genomes database and comparative analysis system. *Nucleic Acids Res.* 40:D115–D122. <http://dx.doi.org/10.1093/nar/gkr1044>.
- Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA,

- Formis K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST Server: rapid annotations using subsystems technology. *BMC Genomics* 9:75. <http://dx.doi.org/10.1186/1471-2164-9-75>.
26. Henry CS, DeJongh M, Best AA, Frybarger PM, Linsay B, Stevens RL. 2010. High-throughput generation, optimization and analysis of genome-scale metabolic models. *Nat. Biotechnol.* 28:977–982. <http://dx.doi.org/10.1038/nbt.1672>.
27. Schellenberger J, Que R, Fleming RM, Thiele I, Orth JD, Feist AM, Zielinski DC, Bordbar A, Lewis NE, Rahmanian S, Kang J, Hyduke DR, Palsson BO. 2011. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. *Nat. Protoc.* 6:1290–1307. <http://dx.doi.org/10.1038/nprot.2011.308>.
28. Heinken A, Sahoo S, Fleming RM, Thiele I. 2013. Systems-level characterization of a host-microbe metabolic symbiosis in the mammalian gut. *Gut Microbes* 4:28–40. <http://dx.doi.org/10.4161/gmic.22370>.
29. Schellenberger J, Park JO, Conrad TM, Palsson BO. 2010. BiGG: a Biochemical Genetic and Genomic knowledgebase of large scale metabolic reconstructions. *BMC Bioinformatics* 11:213. <http://dx.doi.org/10.1186/1471-2105-11-213>.
30. Rodionov DA. 2007. Comparative genomic reconstruction of transcriptional regulatory networks in bacteria. *Chem. Rev.* 107:3467–3497. <http://dx.doi.org/10.1021/cr068309+>.
31. Novichkov PS, Rodionov DA, Stavrovskaya ED, Novichkova ES, Kazakov AE, Gelfand MS, Arkin AP, Mironov AA, Dubchak I. 2010. RegPredict: an integrated system for regulon inference in prokaryotes by comparative genomics approach. *Nucleic Acids Res.* 38:W299–W307. <http://dx.doi.org/10.1093/nar/gkq531>.
32. Novichkov PS, Laikova ON, Novichkova ES, Gelfand MS, Arkin AP, Dubchak I, Rodionov DA. 2010. RegPrecise: a database of curated genomic inferences of transcriptional regulatory interactions in prokaryotes. *Nucleic Acids Res.* 38:D111–D118. <http://dx.doi.org/10.1093/nar/gkp894>.
33. Abreu-Goodger C, Merino E. 2005. RibEx: a web server for locating riboswitches and other conserved bacterial regulatory elements. *Nucleic Acids Res.* 33:W690–692. <http://dx.doi.org/10.1093/nar/gki445>.
34. Mo ML, Palsson BO, Herrgard MJ. 2009. Connecting extracellular metabolomic measurements to intracellular flux states in yeast. *BMC Syst. Biol.* 3:37. <http://dx.doi.org/10.1186/1752-0509-3-37>.
35. Edwards JS, Ramakrishna R, Palsson BO. 2002. Characterizing the metabolic phenotype: a phenotype phase plane analysis. *Biotechnol. Bioeng.* 77:27–36. <http://dx.doi.org/10.1002/bit.10047>.
36. Suau A, Rochet V, Sghir A, Gramet G, Brewaeys S, Sutren M, Rigottier-Gois L, Dore J. 2001. *Fusobacterium prausnitzii* and related species represent a dominant group within the human fecal flora. *Syst. Appl. Microbiol.* 24:139–145. <http://dx.doi.org/10.1078/0723-2020-00015>.
37. Benus RFJ, van der Werf TS, Welling GW, Judd PA, Taylor MA, Harmsen HJM, Whelan K. 2010. Association between *Faecalibacterium prausnitzii* and dietary fibre in colonic fermentation in healthy human subjects. *Br. J. Nutr.* 104:693–700. <http://dx.doi.org/10.1017/S000714510001030>.
38. Paglia G, Hrafnisdottir S, Magnusdottir M, Fleming RM, Thorlacius S, Palsson BO, Thiele I. 2012. Monitoring metabolites consumption and secretion in cultured cells using ultra-performance liquid chromatography quadrupole-time of flight mass spectrometry (UPLC-Q-ToF-MS). *Anal. Bioanal. Chem.* 402:1183–1198. <http://dx.doi.org/10.1007/s00216-011-5556-4>.
39. Khan MT, Duncan SH, Stams AJ, van Dijk JM, Flint HJ, Harmsen HJ. 2012. The gut anaerobe *Faecalibacterium prausnitzii* uses an extracellular electron shuttle to grow at oxic-anoxic interphases. *ISME J.* 6:1578–1585. <http://dx.doi.org/10.1038/ismej.2012.5>.
40. Ames TD, Rodionov DA, Weinberg Z, Breaker RR. 2010. A eubacterial riboswitch class that senses the coenzyme tetrahydrofolate. *Chem. Biol.* 17:681–685. <http://dx.doi.org/10.1016/j.chembiol.2010.05.020>.
41. Russell WR, Duncan SH, Scobbie L, Duncan G, Cantlay L, Calder AG, Anderson SE, Flint HJ. 2013. Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. *Mol. Nutr. Food Res.* 57:523–535. <http://dx.doi.org/10.1002/mnfr.201200594>.
42. Rodionov DA, Hebbeln P, Eudes A, ter Beek J, Rodionova IA, Erkens GB, Slotboom DJ, Gelfand MS, Osterman AL, Hanson AD, Eitinger T. 2009. A novel class of modular transporters for vitamins in prokaryotes. *J. Bacteriol.* 191:42–51. <http://dx.doi.org/10.1128/JB.01208-08>.
43. Khan MT. 2013. Novel physiological and metabolic insights into the beneficial gut microbe *Faecalibacterium prausnitzii*—from carbohydrates to current. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
44. Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, Hooper LV, Gordon JI. 2003. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. *Science* 299:2074–2076. <http://dx.doi.org/10.1126/science.1080029>.
45. Brigham CJ, Malamy MH. 2005. Characterization of the RokA and HexA broad-substrate-specificity hexokinases from *Bacteroides fragilis* and their role in hexose and N-acetylglucosamine utilization. *J. Bacteriol.* 187:890–901. <http://dx.doi.org/10.1128/JB.187.3.890-901.2005>.
46. Orth JD, Thiele I, Palsson BO. 2010. What is flux balance analysis? *Nat. Biotechnol.* 28:245–248. <http://dx.doi.org/10.1038/nbt.1614>.
47. Bautista EJ, Zinski J, Szczepanek SM, Johnson EL, Tulman ER, Ching WM, Geary SJ, Srivastava R. 2013. Semi-automated curation of metabolic models via flux balance analysis: a case study with *Mycoplasma gallisepticum*. *Plos Comput. Biol.* 9:e1003208. <http://dx.doi.org/10.1371/journal.pcbi.1003208>.
48. Dreyfuss JM, Zucker JD, Hood HM, Ocasio LR, Sachs MS, Galagan JE. 2013. Reconstruction and validation of a genome-scale metabolic model for the filamentous fungus *Neurospora crassa* using FARM. *PLoS Comput. Biol.* 9:e1003126. <http://dx.doi.org/10.1371/journal.pcbi.1003126>.
49. Covert MW, Knight EM, Reed JL, Herrgard MJ, Palsson BO. 2004. Integrating high-throughput and computational data elucidates bacterial networks. *Nature* 429:92–96. <http://dx.doi.org/10.1038/nature02456>.
50. Karr JR, Sanghvi JC, Macklin DN, Gutschow MV, Jacobs JM, Bolival B, Jr, Assad-Garcia N, Glass JI, Covert MW. 2012. A whole-cell computational model predicts phenotype from genotype. *Cell* 150:389–401. <http://dx.doi.org/10.1016/j.cell.2012.05.044>.
51. Thiele I, Fleming RM, Que R, Bordbar A, Diep D, Palsson BO. 2012. Multiscale modeling of metabolism and macromolecular synthesis in *E. coli* and its application to the evolution of codon usage. *PLoS One* 7:e45635. <http://dx.doi.org/10.1371/journal.pone.0045635>.
52. Thiele I, Fleming RM, Bordbar A, Schellenberger J, Palsson BO. 2010. Functional characterization of alternate optimal solutions of *Escherichia coli*'s transcriptional and translational machinery. *Biophys. J.* 98:2072–2081. <http://dx.doi.org/10.1016/j.bpj.2010.01.060>.
53. Sun Y, Fleming RM, Thiele I, Saunders MA. 2013. Robust flux balance analysis of multiscale biochemical reaction networks. *BMC Bioinformatics* 14:240. <http://dx.doi.org/10.1186/1471-2105-14-240>.
54. Khan MT, Browne WR, van Dijk JM, Harmsen HJ. 2012. How can *Faecalibacterium prausnitzii* employ riboflavin for extracellular electron transfer? *Antioxid. Redox Signal.* 17:1433–1440. <http://dx.doi.org/10.1089/ars.2012.4701>.
55. Almagro-Moreno S, Boyd EF. 2009. Insights into the evolution of sialic acid catabolism among bacteria. *BMC Evol. Biol.* 9:118. <http://dx.doi.org/10.1186/1471-2148-9-118>.
56. El-Semman IE, Karlsson FH, Shoaie S, Nookaew I, Soliman TH, Nielsen J. 2014. Genome-scale metabolic reconstructions of *Bifidobacterium adolescentis* L2-32 and *Faecalibacterium prausnitzii* A2-165 and their interaction. *BMC Syst. Biol.* 8:41. <http://dx.doi.org/10.1186/1752-0509-8-41>.
57. Karlsson FH, Nookaew I, Petranovic D, Nielsen J. 2011. Prospects for systems biology and modeling of the gut microbiome. *Trends Biotechnol.* 29:251–258. <http://dx.doi.org/10.1016/j.tibtech.2011.01.009>.
58. Smith K, McCoy KD, Macpherson AJ. 2007. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. *Semin. Immunol.* 19:59–69. <http://dx.doi.org/10.1016/j.smim.2006.10.002>.
59. Mahowald MA, Rey FE, Seedorf H, Turnbaugh PJ, Fulton RS, Wollam A, Shah N, Wang C, Magrini V, Wilson RK, Cantarel BL, Coutinho PM, Henrissat B, Crock LW, Russell A, Verberkmoes NC, Hettich RL, Gordon JI. 2009. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. *Proc. Natl. Acad. Sci. U. S. A.* 106:5859–5864. <http://dx.doi.org/10.1073/pnas.0901529106>.
60. Wrzosek L, Miquel S, Noordine ML, Bouet S, Chevalier-Curt MJ, Robert V, Philippe C, Bridonneau C, Cherbuy C, Revell-Masselot C, Langella P, Thomas M. 2013. *Bacteroides thetaiotaomicron* and *Faecali-*

- bacterium *prausnitzii* influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. *BMC Biol.* 11:61. <http://dx.doi.org/10.1186/1741-7007-11-61>.
61. Ze X, Le Mougen F, Duncan SH, Louis P, Flint HJ. 2013. Some are more equal than others: the role of “keystone” species in the degradation of recalcitrant substrates. *Gut Microbes* 4:236–240. <http://dx.doi.org/10.4161/gmic.23998>.
62. Duncan SH, Louis P, Thomson JM, Flint HJ. 2009. The role of pH in determining the species composition of the human colonic microbiota. *Environ. Microbiol.* 11:2112–2122. <http://dx.doi.org/10.1111/j.1462-2920.2009.01931.x>.